Research programme: sialidase fusion protein therapeutics - Ansun Biopharma
Alternative Names: AvSialidase armed VVLatest Information Update: 30 Jun 2023
At a glance
- Originator Ansun Biopharma
- Class Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Neuraminidase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Colorectal cancer; Malignant melanoma
Most Recent Events
- 20 Jun 2023 Early research in Breast cancer in USA (unspecified route), prior to April 2023 (Ansun Biopharma pipeline, June 2023)
- 20 Jun 2023 Early research in Colorectal cancer in USA (unspecified route) prior to April 2023 (Ansun Biopharma pipeline, June 2023)
- 20 Jun 2023 Early research in Malignant melanoma in USA (unspecified route) prior to April 2023 (Ansun Biopharma pipeline, June 2023)